Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
TRVI Trevi Therapeutics
1.5400.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
ROIC
38.97% -57.278% -34.91% -101.182% -32.78% -89.482% -32.78% -89.482%
ROE
34.4% -79.631% -107.95% -192.679% -91.13% -153.031% -91.13% -153.031%
ROA
36.51% -51.684% -33.54% -89.824% -29.66% -79.293% -29.66% -79.293%
Efficiency Ratios
ROA 5 Year Average
-- -- -- -- -- -69.935% -- --
Profitability Ratios TTM
Financial Health Ratios
Long-Term Debt to Equity Ratio
-86.74% 8.975% 17.11% 67.438% -1.67% 50.811% -1.67% 50.811%
Total Assets to Common Equity
-39.05% 134.535% 60.47% 290.414% 30.43% 225.329% 30.43% 225.329%
Debt to Asset Ratio
-74.59% 20.694% 124% 135.516% 64.48% 85.675% 64.48% 85.675%
Current Ratio
26.58% 5.1762 -70.64% 2.319 -64.19% 2.9831 -64.19% 2.9831
Quick Ratio
30.32% 5.0447 -70.95% 2.2626 -64.25% 2.9135 -64.25% 2.9135
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- -- 0.000% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
CEO: Good, Jennifer L.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top